Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:ssspta1653hxp
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2	Dec 17	The CA Lexicon available in the CAPLUS and CA files
NEWS 3	Feb 06	Engineering Information Encompass files have new names
NEWS 4	Feb 16	TOXLINE no longer being updated
NEWS 5	Apr 23	Search Derwent WPINDEX by chemical structure
NEWS 6	Apr 23	PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA

NEWS EXPRESS	April 18 CURRENT WINDOWS VERSION IS V6.0, CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP), AND CURRENT DISCOVER FILE IS DATED 04/06
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 12:57:47 ON 27 APR 2001

=> file medline, biosis, dgene, uspat, hcaplus, embase, scisearch, biotechabs, biotechds, uspat, wpids, japio, jicst, fsta, frosti, cen, ceaba

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.30	0.30

FILE 'MEDLINE' ENTERED AT 12:58:54 ON 27 APR 2001

FILE 'BIOSIS' ENTERED AT 12:58:54 ON 27 APR 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'DGENE' ENTERED AT 12:58:54 ON 27 APR 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'USPATFULL' ENTERED AT 12:58:54 ON 27 APR 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

```
FILE 'HCAPLUS' ENTERED AT 12:58:54 ON 27 APR 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 12:58:54 ON 27 APR 2001
COPYRIGHT (C) 2001 Elsevier Science B.V.  All rights reserved.

FILE 'SCISEARCH' ENTERED AT 12:58:54 ON 27 APR 2001
COPYRIGHT (C) 2001 Institute for Scientific Information (ISI) (R)

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 12:58:54 ON 27 APR 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'WPIDS' ENTERED AT 12:58:54 ON 27 APR 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'JAPIO' ENTERED AT 12:58:54 ON 27 APR 2001
COPYRIGHT (C) 2001 Japanese Patent Office (JPO)

FILE 'JICST-EPLUS' ENTERED AT 12:58:54 ON 27 APR 2001
COPYRIGHT (C) 2001 Japan Science and Technology Corporation (JST)

FILE 'FSTA' ENTERED AT 12:58:54 ON 27 APR 2001
COPYRIGHT (C) 2001 International Food Information Service

FILE 'FROSTI' ENTERED AT 12:58:54 ON 27 APR 2001
COPYRIGHT (C) 2001 Leatherhead Food Research Association

FILE 'CEN' ENTERED AT 12:58:54 ON 27 APR 2001
COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'CEABA-VTB' ENTERED AT 12:58:54 ON 27 APR 2001
COPYRIGHT (c) 2001 DECHEMA eV

=> s multidrug resistance

L1       40264 MULTIDRUG RESISTANCE

=> s annexin

L2       12885 ANNEXIN

=> s l2 and type one

   9 FILES SEARCHED...
L3           0 L2 AND TYPE ONE

=> s l2 and l1

L4          81 L2 AND L1

=> s l4 and p-40

L5          13 L4 AND P-40

=> s l5 and method

L6          10 L5 AND METHOD

=> d l6 ti abs ibib tot
```

L6 ANSWER 1 OF 10 USPATFULL
TI Antibodies to a **multidrug resistance** protein
AB A novel protein associated with **multidrug resistance** in living cells and capable of conferring **multidrug resistance** on a cell is disclosed. Nucleic acids encoding the novel **multidrug resistance** protein are also disclosed. Transformant cell lines which express the nucleic acid encoding the novel protein are also disclosed. Antibodies which bind the novel **multidrug resistance** protein are also disclosed. Diagnostic and treatment methods using the novel proteins, nucleic acids, antibodies and cell lines of the invention are also encompassed by the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2000:61437 USPATFULL	
TITLE:	Antibodies to a **multidrug resistance** protein	
INVENTOR(S):	Deeley, Roger G., Kingston, Canada Cole, Susan P. C., Kingston, Canada	
PATENT ASSIGNEE(S):	Queen's University at Kingston, Kingston, Canada (non-U.S. corporation)	
	NUMBER	DATE
PATENT INFORMATION:	US 6063621	20000516
APPLICATION INFO.:	US 1995-407207	19950320 (8)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 1993-141893, filed on 26 Oct 1993, now patented, Pat. No. US 5489519 which is a continuation-in-part of Ser. No. US 1993-29340, filed on 8 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-966923, filed on 27 Oct 1992, now abandoned	
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	Huff, Sheela	
ASSISTANT EXAMINER:	Reeves, Julie E	
LEGAL REPRESENTATIVE:	Steeg, Carol Miernicki; Kara, Catherine J.; DeConti, Jr., Giulio A.	
NUMBER OF CLAIMS:	20	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	23 Drawing Figure(s); 21 Drawing Page(s)	
LINE COUNT:	3685	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 10 USPATFULL
TI **Multidrug resistance** proteins
AB A novel protein associated with **multidrug resistance** in living cells and capable of conferring **multidrug resistance** on a cell is disclosed. Nucleic acids encoding the novel **multidrug resistance** protein are also disclosed. Transformant cell lines which express the nucleic acid encoding the novel protein are also disclosed. Antibodies which bind the novel **multidrug resistance** protein are also disclosed. Diagnostic and treatment methods using the novel proteins, nucleic acids, antibodies and cell lines of the invention are also encompassed by the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2000:18558 USPATFULL
TITLE:	**Multidrug resistance** proteins

INVENTOR(S): Deeley, Roger G., Kingston, Canada
Cole, Susan P. C., Kingston, Canada
PATENT ASSIGNEE(S): Queen's University at Kingston, Kingston, Canada
(non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6025473	20000215
APPLICATION INFO.:	US 1995-461384	19950605 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-407207, filed on 20 Mar 1995 which is a continuation-in-part of Ser. No. US 1993-141893, filed on 26 Oct 1993, now patented,

Pat. No. US 5489519 which is a continuation-in-part of Ser. No. US 1993-29340, filed on 8 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-966923, filed on 27 Oct 1992, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Burke, Julie
LEGAL REPRESENTATIVE: Steeg, Carol Miernicki; Kara, Catherine J.; DeConti, Jr., Giulio A.
NUMBER OF CLAIMS: 19
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 23 Drawing Figure(s); 21 Drawing Page(s)
LINE COUNT: 4915
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 3 OF 10 USPATFULL
TI Methods for identifying chemosensitizers
AB A novel protein associated with **multidrug resistance** in living cells and capable of conferring **multidrug resistance** on a cell is disclosed. Nucleic acids encoding the novel **multidrug resistance** protein are also disclosed. Transformant cell lines which express the nucleic acid encoding the novel protein are also disclosed. Antibodies which bind the novel **multidrug resistance** protein are also disclosed. Diagnostic and treatment methods using the novel proteins, nucleic acids, antibodies and cell lines of the invention are also encompassed by the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1999:163419 USPATFULL
TITLE: Methods for identifying chemosensitizers
INVENTOR(S): Deeley, Roger G., Kingston, Canada
Cole, Susan P.C., Kingston, Canada
PATENT ASSIGNEE(S): Queen's University at Kingston, Kingston, Canada
(non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6001563	19991214
APPLICATION INFO.:	US 1995-463179	19950605 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-407207, filed on 20 Mar 1995 which is a continuation-in-part of Ser. No. US 1993-141893, filed on 26 Oct 1993, now patented,

Pat. No. US 5489519, issued on 6 Feb 1996 which is a continuation-in-part of Ser. No. US 1993-29340, filed on 8 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-966923, filed on 27 Oct 1992, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Stanton, Brian R.

ASSISTANT EXAMINER: Clark, Deborah J. R.
LEGAL REPRESENTATIVE: Steeg, Carol Miernicki; Kara, Catherine J.; DeConti, Jr., Giulio A.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1,7
NUMBER OF DRAWINGS: 13 Drawing Figure(s); 21 Drawing Page(s)
LINE COUNT: 4885
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 4 OF 10 USPATFULL
TI Methods for conferring **multidrug resistance** on a cell
AB A novel protein associated with **multidrug resistance** in living cells and capable of conferring **multidrug resistance** on a cell is disclosed. Nucleic acids encoding the novel **multidrug resistance** protein are also disclosed. Transformant cell lines which express the nucleic acid encoding the novel protein are also disclosed. Antibodies which bind the novel **multidrug resistance** protein are also disclosed. Diagnostic and treatment methods using the novel proteins, nucleic acids, antibodies and cell lines of the invention are also encompassed by the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1999:43471 USPATFULL
TITLE: Methods for conferring **multidrug resistance** on a cell
INVENTOR(S): Deeley, Roger G., Kingston, Canada
Cole, Susan P. C., Kingston, Canada
PATENT ASSIGNEE(S): Queen's University at Kingston, Kingston, Canada (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5891724	19990406
APPLICATION INFO.:	US 1995-460907	19950605 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-407207, filed on 20 Mar 1995 which is a continuation-in-part of Ser. No. US 1993-141893, filed on 26 Oct 1993, now patented, Pat. No. US 5489519, issued on 6 Feb 1996 which is a continuation-in-part of Ser. No. US 1993-29340, filed on 8 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-966923, filed on 27 Oct 1992, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: LaGuyader, John L.
ASSISTANT EXAMINER: Schwartzman, Robert
LEGAL REPRESENTATIVE: Steeg, Carol Mlernicki; Kara, Catherine J.; DeConti, Jr., Giulio A.
NUMBER OF CLAIMS: 21
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 26 Drawing Figure(s); 21 Drawing Page(s)
LINE COUNT: 4215
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 5 OF 10 USPATFULL
TI Methods for identifying multidrug resistant tumor cells
AB A novel protein associated with **multidrug resistance** in living cells and capable of conferring **multidrug resistance** on a cell is disclosed. Nucleic acids encoding the novel **multidrug resistance** protein are also disclosed. Transformant cell lines which express the nucleic acid

encoding the novel protein are also disclosed. Antibodies which bind the
novel **multidrug sistance** protein are also disclosed. Diagnostic and treatment methods using the novel proteins, nucleic acids, antibodies and cell lines of the invention are also encompassed by the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1999:33784 USPATFULL
TITLE:	Methods for identifying multidrug resistant tumor cells
INVENTOR(S):	Deeley, Roger G., Kingston, Canada Cole, Susan P. C., Kingston, Canada
PATENT ASSIGNEE(S):	Queen's University at Kingston, Kingston, Canada (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5882875	19990316
APPLICATION INFO.:	US 1995-462109	19950605 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-407207, filed on 20 Mar 1995 which is a continuation-in-part of Ser. No. US 1993-141893, filed on 26 Oct 1993, now patented, Pat. No. US 5489519, issued on 6 Feb 1996 which is a continuation-in-part of Ser. No. US 1993-29340, filed on 8 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-966923, filed on 27 Oct 1992, now abandoned

DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	Huff, Sheela
ASSISTANT EXAMINER:	Reeves, Julie E
LEGAL REPRESENTATIVE:	Steeg, Carol Miernicki; Kara, Catherine J.; DeConti, Jr., Giulio A.
NUMBER OF CLAIMS:	17
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	26 Drawing Figure(s); 21 Drawing Page(s)
LINE COUNT:	4149

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 6 OF 10 USPATFULL

TI Isolated nucleic acid molecules encoding **multidrug resistance** proteins

AB A novel protein associated with **multidrug resistance** in living cells and capable of conferring **multidrug resistance** on a cell is disclosed. Nucleic acids encoding the novel **multidrug resistance** protein are also disclosed. Transformant cell lines which express the nucleic acid encoding the novel protein are also disclosed. Antibodies which bind the
novel **multidrug resistance** protein are also disclosed. Diagnostic and treatment methods using the novel proteins, nucleic acids, antibodies and cell lines of the invention are also encompassed by the invention.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1998:68805 USPATFULL
TITLE:	Isolated nucleic acid molecules encoding **multidrug resistance** proteins
INVENTOR(S):	Deeley, Roger G., Kingston, Canada Cole, Susan P.C., Kingston, Canada
PATENT ASSIGNEE(S):	Queen's University at Kingston, Kingston, Canada (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5766880	19980616
APPLICATION INFO.:	US 1995-463092	19950605 (8)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1995-407207, filed on 20 Mar 1995 which is a continuation-in-part of Ser. No. US 1993-141893, filed on 26 Oct 1993, now patented,

Pat. No. US 5489519, issued on 6 Feb 1996 which is a continuation-in-part of Ser. No. US 1993-29340, filed on 8 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-966923, filed on 27 Oct 1992, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Elliott, George C.
ASSISTANT EXAMINER: Schwarteman, Robert
LEGAL REPRESENTATIVE: Steeg, Carol Miernicki; Kara, Catherine J.; DeConti, Jr., Giulio A.
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 30 Drawing Figure(s); 21 Drawing Page(s)
LINE COUNT: 3632
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 7 OF 10 USPATFULL
TI **Multidrug resistance** protein
AB A novel protein associated with **multidrug resistance** in living cells and capable of conferring **multidrug resistance** on a cell is disclosed and nucleic acids encoding the novel isoforms are disclosed. Transformant cell lines which express the nucleic acid encoding the novel protein are also disclosed. Further, diagnostic and treatment methods using the novel protein, nucleic acids and cell lines are also disclosed.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 96:11065 USPATFULL
TITLE: **Multidrug resistance** protein
INVENTOR(S): Deeley, Roger G., Kingston, Canada
Cole, Susan P. C., Kingston, Canada
PATENT ASSIGNEE(S): Queen's University at Kingston, Kingston, Canada (non-U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5489519	19960206
APPLICATION INFO.:	US 1993-141893	19931026 (3)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1993-29340, filed on 8 Mar 1993, now abandoned which is a continuation-in-part of Ser. No. US 1992-966923, filed on 27 Oct 1992, now abandoned

DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Furman, Keith C.
LEGAL REPRESENTATIVE: Lahive & Cockfield
NUMBER OF CLAIMS: 33
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 22 Drawing Figure(s); 17 Drawing Page(s)
LINE COUNT: 2919
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 8 OF 10 HCAPLUS COPYRIGHT 2001 ACS
TI Identification of **P-40** as **Annexin** I and its role in **multidrug resistance**
AB The invention identifies **P-40** as **Annexin** I, a member of a large family of calcium-dependent phospholipid binding

proteins implicated in intracellular membrane vascular trafficking and exocytosis proces[illegible]. The overexpression of **P-40** alone or together [illegible]th P-glycoprotein (P-gp) or th[illegible]**ultidrug resistance** assocd. protein (MRP) in MDR cell lines has been previously reported, but this invention is the first to show the role of **Annexin** I (**P-40**) overexpression in the resistance of tumor cells to Taxol and adriamycin, the identification of its gene as a member of the MDR gene family, and the existence of an **Annexin**-based **multidrug resistance** pathway. Also provided is a **method** of reducing **Annexin**-based MDR in a cell or animal, comprising the step of administering a therapeutically effective amt. of a pharmaceutical compn. according to the invention.

ACCESSION NUMBER: 1999:299504 HCAPLUS
DOCUMENT NUMBER: 130:308198
TITLE: Identification of **P-40** as **Annexin** I and its role in **multidrug resistance**
INVENTOR(S): Georges, Elias; Wang, Ying
PATENT ASSIGNEE(S): McGill University, Can.
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9921980	A1	19990506	WO 1998-CA992	19981026
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2219299	AA	19990424	CA 1997-2219299	19971024
AU 9896174	A1	19990517	AU 1998-96174	19981026
EP 1025225	A1	20000809	EP 1998-949842	19981026
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				

PRIORITY APPLN. INFO.: CA 1997-2219299 A 19971024
WO 1998-CA992 W 19981026

REFERENCE COUNT: 6
REFERENCE(S):
(2) Biogen Nv; WO 8604094 A 1986 HCAPLUS
(3) Carollo, M; ONCOLOGY RESEARCH 1998, V10(5), P245 HCAPLUS
(4) Cole, S; BRITISH JOURNAL OF CANCER 1992, V65(4), P498 HCAPLUS
(5) Horseman, N; GENERAL AND COMPARARTIVE ENDOCRINOLOGY 1992, V85(3), P405 HCAPLUS
(6) Wang, Y; BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 1997, V236(2), P483 HCAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 9 OF 10 BIOTECHDS COPYRIGHT 2001 DERWENT INFORMATION LTD
TI Modulating or assessing **multidrug-resistance** related to **annexin** protein; recombinant **annexin**, DNA probe and antisense DNA, useful for the reversal of cancer therapy-induced **multidrug-resistance** and for drug screening for e.g. fungicide

AN 1999-09800 BIOTECHDS
AB An isolated DNA sequence (I) encoding an **annexin** family member (II), i.e. a member of the **multidrug-resistance** ([redacted]) family, for assessing or modulating MDR in a cell is new. Also claimed are: detection and assessment of **annexin**-based MDR using a DNA probe; kits for this **method**; a recombinant vector, preferably plasmid pCDNA3/**P-40** or plasmid pC1N4P-40, for modulating **annexin**-based MDR in a cell; host cells e.g. mammal, parasitic, fungal cells containing this vector; a drug screening **method** to identify agents that affect **annexin**-based MDR; a **method** of reducing **annexin**-based MDR by administering a nucleic acid dominant negative mutant of **annexin**, **annexin**-specific antibody or a peptide or small molecule; a pharmaceutical composition for reducing MDR comprising an **annexin**-based MDR-modulating compound; and methods for diagnosing the presence of, or predisposition to, **annexin**-based MDR in a patient or pathogen. Antisense sequences to (I) are useful for preventing MDR in animals, particularly in conjunction with cancer therapy. (II) is useful as a target for identifying e.g. fungicides and increasing (II) expression in plants to develop specific resistances. (62pp)
ACCESSION NUMBER: 1999-09800 BIOTECHDS
TITLE: Modulating or assessing **multidrug-resistance** related to **annexin** protein; recombinant **annexin**, DNA probe and antisense DNA, useful for the reversal of cancer therapy-induced **multidrug-resistance** and for drug screening for e.g. fungicide
AUTHOR: Georges E; Wang Y
PATENT ASSIGNEE: Univ.McGill
LOCATION: Montreal, Quebec, Canada.
PATENT INFO: WO 9921980 6 May 1999
APPLICATION INFO: WO 1998-CA992 26 Oct 1998
PRIORITY INFO: CA 1997-2219299 24 Oct 1997
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: WPI: 1999-337419 [28]

L6 ANSWER 10 OF 10 WPIDS COPYRIGHT 2001 DERWENT INFORMATION LTD
TI Modulating or assessing **multidrug resistance** related to **annexin** proteins.
AN 1999-337419 [28] WPIDS
AB WO 9921980 A UPAB: 19990719
NOVELTY - Isolated nucleic acid (I) encoding an **annexin** family member (II), i.e. a member of the MDR (**multidrug resistance**) gene family, for assessing or modulating MDR in a cell, is new.
DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:
(1) a **method** for detecting and assessing **annexin**-based MDR by treating test sample with an oligonucleotide (ON) containing 10-50 nucleotides (nt) that hybridize specifically to RNA and/or DNA encoding an **annexin**, ON being complementary to a sequence of at least 10 consecutive nt from the sequences for annexins I to IX, and detecting any hybrids formed;
(2) kits for this **method**;
(3) recombinant vector for modulating, inhibiting and/or increasing **annexin**-based MDR in a cell, containing (I) linked to a promoter;
(4) cells containing this vector;
(5) a **method** for identifying compounds that affect **annexin**-based MDR by incubating with test compound in presence or absence of a drug and assessing any effect of the test compound on resistance to the drug;

(6) a **method** of reducing **annexin**-based MDR by administering a nucleic acid, (dominant negative) mutant of **annexin**, antibody to **annexin**, peptide or small molecule;

(7) pharmaceutical composition for reducing MDR comprising **annexin**-based MDR-affecting compound and a carrier; and

(8) methods for diagnosing presence of, or predisposition to, **annexin**-based MDR in a patient or pathogen.

ACTIVITY - Antitumor; antifungal.

MECHANISM OF ACTION - None given.

USE - Antisense sequences from (I), or any other agent that inhibits (II), are used to prevent MDR in animals, particularly in conjunction with cancer treatment. Detecting levels of (II), or related RNA, is used to detect cancer (or pathogens) with MDR, or susceptibility. (II) can also be used as a target for identifying therapeutic agents, e.g. antifungal agents, and increasing (II) expression in plants may be used to develop specific resistance.

Dwg.0/9

ACCESSION NUMBER: 1999-337419 [28] WPIDS
DOC. NO. NON-CPI: N1999-252873
DOC. NO. CPI: C1999-099183
TITLE: Modulating or assessing **multidrug resistance** related to **annexin** proteins.
DERWENT CLASS: B04 D16 S03
INVENTOR(S): GEORGES, E; WANG, Y
PATENT ASSIGNEE(S): (UYMC-N) UNIV MCGILL; (GEOR-I) GEORGES E; (WANG-I) WANG Y
COUNTRY COUNT: 83
PATENT INFORMATION:

PATENT NO	KIND	DATE	WEEK	LA	PG
WO 9921980	A1	19990506	(199928)*	EN	62
RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW					
W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW					
AU 9896174	A	19990517	(199939)		
CA 2219299	A1	19990424	(199940)	EN	
EP 1025225	A1	20000809	(200039)	EN	
R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE					

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 9921980	A1	WO 1998-CA992	19981026
AU 9896174	A	AU 1998-96174	19981026
CA 2219299	A1	CA 1997-2219299	19971024
EP 1025225	A1	EP 1998-949842	19981026
		WO 1998-CA992	19981026

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9896174	A	Based on	WO 9921980
EP 1025225	A1	Based on	WO 9921980

PRIORITY APPLN. INFO: CA 1997-2219299 19971024

```
=> e georges, e/au

E1            1     GEORGES YVES MARTHE/AU
E2            1     GEORGES Z/AU
E3            0 --> GEORGES, E/AU
E4            5     GEORGESC C/AU
E5            4     GEORGESC D/AU
E6            2     GEORGESC II/AU
E7            3     GEORGESC M/AU
E8            2     GEORGESC S/AU
E9            1     GEORGESC V/AU
E10           1     GEORGESCA L/AU
E11           1     GEORGESCALUD D/AU
E12           5     GEORGESCAUD D/AU

=> e wang, Y/au

E1            1     WANG ZXINGTAI/AU
E2            2     WANG ZYX/AU
E3            0 --> WANG, Y/AU
E4            1     WANG1 Y/AU
E5            1     WANGA A P/AU
E6            1     WANGA C/AU
E7            1     WANGA C C/AU
E8            1     WANGA D/AU
E9            1     WANGA D B/AU
E10           1     WANGA G/AU
E11           1     WANGA G J/AU
E12           1     WANGA K C/AU
```

```
Trying 3106016892...Open

Welcome to STN International!  Enter x:x
LOGINID:ssspta1653hxp
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2


* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *

 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Dec 17  The CA Lexicon available in the CAPLUS and CA files
 NEWS  3  Feb 06  Engineering Information Encompass files have new names
 NEWS  4  Feb 16  TOXLINE no longer being updated
 NEWS  5  Apr 23  Search Derwent WPINDEX by chemical structure
 NEWS  6  Apr 23  PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA

 NEWS EXPRESS  April 18 CURRENT WINDOWS VERSION IS V6.0,
               CURRENT MACINTOSH VERSION IS V5.0C (ENG) AND V5.0JB (JP),
               AND CURRENT DISCOVER FILE IS DATED 04/06
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 13:29:23 ON 27 APR 2001

=> file medline, biosis, dgene, uspat, hcaplus, wpids, biotechds, frosti,
fsta, jicst, japio

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       0.30       0.30

FILE 'MEDLINE' ENTERED AT 13:30:11 ON 27 APR 2001

FILE 'BIOSIS' ENTERED AT 13:30:11 ON 27 APR 2001
COPYRIGHT (C) 2001 BIOSIS(R)

FILE 'DGENE' ENTERED AT 13:30:11 ON 27 APR 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'USPATFULL' ENTERED AT 13:30:11 ON 27 APR 2001
CA INDEXING COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE 'HCAPLUS' ENTERED AT 13:30:11 ON 27 APR 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'WPIDS' ENTERED AT 13:30:11 ON 27 APR 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'BIOTECHDS' ENTERED AT 13:30:11 ON 27 APR 2001
COPYRIGHT (C) 2001 DERWENT INFORMATION LTD

FILE 'FROSTI' ENTERED AT 13:30:11 ON 27 APR 2001
COPYRIGHT (C) 2001 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 13:30:11 ON 27 APR 2001
COPYRIGHT (C) 2001 International Food Information Service

FILE 'JICST-EPLUS' ENTERED AT 13:30:11 ON 27 APR 2001
COPYRIGHT (C) 2001 Japan Science and Technology Corporation (JST)

FILE 'JAPIO' ENTERED AT 13:30:11 ON 27 APR 2001
COPYRIGHT (C) 2001 Japanese Patent Office (JPO)

=> multidrug resisitance

MULTIDRUG IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s MDR or multidrug resistance

L1 28120 MDR OR MULTIDRUG RESISTANCE

=> s p-40

L2 10653 P-40

=> s mcf-7 cells

L3 9068 MCF-7 CELLS

=> s l3 and l2

L4 32 L3 AND L2

=> s l1 and l4

L5 1 L1 AND L4

=> d l5 ti abs ibib tot

L5 ANSWER 1 OF 1 USPATFULL
TI Inadone and tetralone compounds for inhibiting cell proliferation
AB A new family of inadone and tetralone tubulin-binding compounds (TBs) is
disclosed. Unlike classical TBs, which inhibit mitosis among affected dividing cells, the TBs of the invention possess two unique properties: (1) they induce apoptosis among stationary phase (non-dividing) malignant cells, yet do not impair the viability of normal nonproliferating cells; and, (2) they affect cells which have acquired **MDR** more powerfully than they affect cells without **MDR**

. Thus, the TBs of the invention provide means to target malignant cells
for chemotherapy even after previous therapies e failed, without affecting normal cells and tissues in the host.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2000:171034 USPATFULL
TITLE:	Inadone and tetralone compounds for inhibiting cell proliferation
INVENTOR(S):	Carson, Dennis A., Del Mar, CA, United States Shih, Hsien C., San Diego, CA, United States Cottam, Howard B., Fallbrook, CA, United States Leoni, Lorenzo, San Diego, CA, United States
PATENT ASSIGNEE(S):	The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6162810	20001219
APPLICATION INFO.:	US 1998-148576	19980904 (9)
DOCUMENT TYPE:	Utility	
PRIMARY EXAMINER:	McKane, Joseph K.	
ASSISTANT EXAMINER:	Solola, Taofiq A.	
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew, LLP	
NUMBER OF CLAIMS:	42	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 5 Drawing Page(s)	
LINE COUNT:	1308	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 13:29:23 ON 27 APR 2001)

FILE 'MEDLINE, BIOSIS, DGENE, USPATFULL, HCAPLUS, WPIDS, BIOTECHDS, FROSTI, FSTA, JICST-EPLUS, JAPIO' ENTERED AT 13:30:11 ON 27 APR 2001

```
L1        28120 S MDR OR MULTIDRUG RESISTANCE
L2        10653 S P-40
L3         9068 S MCF-7 CELLS
L4           32 S L3 AND L2
L5            1 S L1 AND L4

=> s l4 and taxol

L6            1 L4 AND TAXOL

=> s l4 and adriamycin

L7            5 L4 AND ADRIAMYCIN

=> s l6 and l7

L8            1 L6 AND L7

=> s l8 and l5

L9            1 L8 AND L5

=> d l7 ti abs ibib tot
```

L7 ANSWER 1 OF 5 USPATFULL

TI Inadone and tetralone compounds for inhibiting cell proliferation
AB A new family of adone and tetralone tubulin-binding compounds (TBs) is disclosed. Unlike classical TBs, which inhibit mitosis among affected dividing cells, the TBs of the invention possess two unique properties: (1) they induce apoptosis among stationary phase (non-dividing) malignant cells, yet do not impair the viability of normal nonproliferating cells; and, (2) they affect cells which have acquired MDR more powerfully than they affect cells without MDR. Thus, the TBs of the invention provide means to target malignant cells for chemotherapy, even after previous therapies have failed, without affecting normal cells and tissues in the host.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2000:171034 USPATFULL
TITLE:	Inadone and tetralone compounds for inhibiting cell proliferation
INVENTOR(S):	Carson, Dennis A., Del Mar, CA, United States Shih, Hsien C., San Diego, CA, United States Cottam, Howard B., Fallbrook, CA, United States Leoni, Lorenzo, San Diego, CA, United States
PATENT ASSIGNEE(S):	The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 6162810	20001219
APPLICATION INFO.:	US 1998-148576	19980904 (9)

DOCUMENT TYPE:	Utility
PRIMARY EXAMINER:	McKane, Joseph K.
ASSISTANT EXAMINER:	Solola, Taofiq A.
LEGAL REPRESENTATIVE:	Townsend and Townsend and Crew, LLP
NUMBER OF CLAIMS:	42
EXEMPLARY CLAIM:	1
NUMBER OF DRAWINGS:	6 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT:	1308

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 5 USPATFULL
TI Methods of use of a ductal carcinoma antigen
AB Monoclonal antibodies to adenocarcinoma cells, and, in particular, breast carcinoma cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies are capable of shrinking solid tumors associated with human breast. The monoclonal antibodies identify an antigen associated with carcinomas of ductal lineage. The monoclonal antibodies, specifically, F36/22 monoclonal antibodies, can be used diagnostically and therapeutically.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	1999:21919 USPATFULL
TITLE:	Methods of use of a ductal carcinoma antigen
INVENTOR(S):	Chu, Tsann Ming, Williamsville, NY, United States Papsidero, Lawrence D., Orchard Park, NY, United States
PATENT ASSIGNEE(S):	Health Research, Inc., Buffalo, NY, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5871936	19990216
APPLICATION INFO.:	US 1997-979691	19971126 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1996-733631, filed on 17 Oct 1996 which is a division of Ser. No. US 1989-408817, filed on 18 Sep 1989, now patented, Pat. No. US 5652114
which is a division of Ser. No. US 1985-775062, filed on 11 Sep 1985, now patented, Pat. No. US 4939240 which
is a continuation-in-part of Ser. No. US 1983-472222, filed on 4 Mar 1983, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Feisee, Lila
ASSISTANT EXAMINER: Ungar, Susan
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 5
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 2577
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 3 OF 5 USPATFULL
TI Purified ductal carcinoma antigen
AB Monoclonal antibodies to adenocarcinoma cells, and, in particular, breast carcinoma cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies are
capable of shrinking solid tumors associated with human breast. The monoclonal antibodies identify an antigen associated with carcinomas of ductal lineage. The monoclonal antibodies, specifically, F36/22 monoclonal antibodies, can be used diagnostically and therapeutically.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER: 1998:101735 USPATFULL
TITLE: Purified ductal carcinoma antigen
INVENTOR(S): Chu, Tsann Ming, Williamsville, NY, United States
Papsidero, Lawrence D., Orchard Park, NY, United States
PATENT ASSIGNEE(S): Health Research, Inc., Buffalo, NY, United States (U.S.
corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5798445	19980825
APPLICATION INFO.:	US 1996-733631	19961017 (8)

RELATED APPLN. INFO.: Division of Ser. No. US 1989-408817, filed on 18 Sep 1989, now patented, Pat. No. US 5652114 which is a division of Ser. No. US 1985-755062, filed on 11 Sep 1985, now patented, Pat. No. US 4939240 which is a continuation-in-part of Ser. No. US 1983-472222, filed on 4 Mar 1983, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Feisee, Lisa
ASSISTANT EXAMINER: Ungar, Susan
LEGAL REPRESENTATIVE: Pennie & Edmonds LLP
NUMBER OF CLAIMS: 3
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 2571
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 4 OF 5 USPATFULL
TI Diagnostic immunoassay methods using monoclonal antibody F36/22 which is
specific for human breast carcinoma cells

AB Monoclonal antibodies to adenocarcinoma cells, and, in particular, breast carcinoma cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies are capable of shrinking solid human breast tumors xenografted in nude mice.

The monoclonal antibodies identify an antigen associated with carcinomas of ductal lineage. The monoclonal antibodies, specifically, F36/22 monoclonal antibodies, can be used diagnostically and therapeutically.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 97:66006 USPATFULL
TITLE: Diagnostic immunoassay methods using monoclonal antibody F36/22 which is specific for human breast carcinoma cells
INVENTOR(S): Chu, Tsann Ming, Williamsville, NY, United States
Papsidero, Lawrence D., Orchard Park, NY, United States
Croghan, Gary A., Rochester, NY, United States
PATENT ASSIGNEE(S): Health Research Inc., Buffalo, NY, United States (U.S. corporation)

	NUMBER	DATE
PATENT INFORMATION:	US 5652114	19970729
APPLICATION INFO.:	US 1989-408817	19890918 (7)

RELATED APPLN. INFO.: Continuation of Ser. No. US 1985-775062, filed on 11 Sep 1985, now patented, Pat. No. US 4939240 which is a continuation-in-part of Ser. No. US 1983-472222, filed on 4 Mar 1983, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Hutzell, Paula K.
LEGAL REPRESENTATIVE: Pennie & Edmonds
NUMBER OF CLAIMS: 17
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 2616
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 5 OF 5 USPATFULL
TI Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
AB Monoclonal antibodies to adenocarcinoma cells, and, in particular, breast carcinoma cells, are produced by a hybridoma formed by fusing mouse lymphocytes and mouse myeloma cells. The monoclonal antibodies are capable of shrinking solid tumors associated with human breast. The monoclonal antibodies identify an antigen associated with carcinomas of ductal lineage. The monoclonal antibodies, specifically, F36/22 monoclonal antibodies, can be used diagnostically and therapeutically.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 90:52969 USPATFULL
TITLE: Monoclonal antibodies to human breast carcinoma cells and their use in diagnosis and therapy
INVENTOR(S): Chu, Tsann M., Williamsville, NY, United States
Papsidero, Lawrence D., Orchard Park, NY, United States
PATENT ASSIGNEE(S): Health Research, Inc., Buffalo, NY, United States (U.S. corporation)

	NUMBER	DATE

	---	---
PATENT INFORMATION:	US 4939240	19900703
APPLICATION INFO.:	US 1985-775062	19850911 (6)

RELATED APPLN. INFO.: Continuation-in-part of Ser. No. US 1983-472222, filed on 4 Mar 1983, now abandoned
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: Moskowitz, Margaret
ASSISTANT EXAMINER: Cheney, Kay E.
LEGAL REPRESENTATIVE: Pennie & Edmonds
NUMBER OF CLAIMS: 7
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 4 Drawing Figure(s); 4 Drawing Page(s)
LINE COUNT: 2486
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

=> d his

(FILE 'HOME' ENTERED AT 13:29:23 ON 27 APR 2001)

FILE 'MEDLINE, BIOSIS, DGENE, USPATFULL, HCAPLUS, WPIDS, BIOTECHDS, FROSTI, FSTA, JICST-EPLUS, JAPIO' ENTERED AT 13:30:11 ON 27 APR 2001

```
L1        28120 S MDR OR MULTIDRUG RESISTANCE
L2        10653 S P-40
L3         9068 S MCF-7 CELLS
L4           32 S L3 AND L2
L5            1 S L1 AND L4
L6            1 S L4 AND TAXOL
L7            5 S L4 AND ADRIAMYCIN
L8            1 S L6 AND L7
L9            1 S L8 AND L5
```

=> d l9 ti abs ibib tot

L9 ANSWER 1 OF 1 USPATFULL
TI Inadone and tetralone compounds for inhibiting cell proliferation
AB A new family of inadone and tetralone tubulin-binding compounds (TBs) is disclosed. Unlike classical TBs, which inhibit mitosis among affected dividing cells, the TBs of the invention possess two unique properties: (1) they induce apoptosis among stationary phase (non-dividing) malignant cells, yet do not impair the viability of normal nonproliferating cells; and, (2) they affect cells which have acquired **MDR** more powerfully than they affect cells without **MDR**. Thus, the TBs of the invention provide means to target malignant cells for chemotherapy, even after previous therapies have failed, without affecting normal cells and tissues in the host.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2000:171034 USPATFULL
TITLE:	Inadone and tetralone compounds for inhibiting cell proliferation
INVENTOR(S):	Carson, Dennis A., Del Mar, CA, United States Shih, Hsien C., San Diego, CA, United States Cottam, Howard B., Fallbrook, CA, United States Leoni, Lorenzo, San Diego, CA, United States
PATENT ASSIGNEE(S):	The Regents of the University of California, Oakland, CA, United States (U.S. corporation)

	NUMBER	DATE
	---	---

PATENT INFORMATION: US 6162810 20001219
APPLICATION INFO.: US 1998-148576 19980904 (9)
DOCUMENT TYPE: Utility
PRIMARY EXAMINER: McKane, Joseph K.
ASSISTANT EXAMINER: Solola, Taofiq A.
LEGAL REPRESENTATIVE: Townsend and Townsend and Crew, LLP
NUMBER OF CLAIMS: 42
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 6 Drawing Figure(s); 5 Drawing Page(s)
LINE COUNT: 1308
CAS INDEXING IS AVAILABLE FOR THIS PATENT.